Drug Development for Rare Diseases -

Drug Development for Rare Diseases

Bo Yang, Yang Song, Yijie Zhou (Herausgeber)

Buch | Hardcover
222 Seiten
2023
Chapman & Hall/CRC (Verlag)
978-0-367-51834-9 (ISBN)
155,85 inkl. MwSt
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers and other stakeholders.
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed

to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence

inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.

Key Features:

• Rare disease.

• Drug development.

• Innovative clinical trial design.

• Regulatory approval.

• Real-world evidence.

Bo Yang is the Vice President, Biometrics and Real World Evidence at Vertex Pharmaceuticals, USA. Yang Song is the Executive Director, Biostatistics Group Head of Pipeline Development at Vertex Pharmaceuticals, USA. Yijie Zhou is the Executive Director, Real World Statistics and Analytics at Vertex Pharmaceuticals, USA.

1. Introduction to Rare Disease Therapy Development 2. Challenges and Opportunities in Rare Disease Drug 3. Developing Drugs for Rare Diseases: Regulatory Strategies 4. Clinical Trial Design and Analysis Considerations for Rare Diseases 5. Use of Real-World Evidence to Support Drug Development 6. Clinical Development of Pediatric Program within Rare Diseases 7. Use of Modeling and Simulation in Support of Drug Development for Rare Diseases 8. Case Studies of Rare Disease Drug Development

Erscheinungsdatum
Reihe/Serie Chapman & Hall/CRC Biostatistics Series
Zusatzinfo 1 Tables, color; 22 Tables, black and white; 5 Line drawings, color; 2 Line drawings, black and white; 5 Illustrations, color; 2 Illustrations, black and white
Sprache englisch
Maße 156 x 234 mm
Gewicht 589 g
Themenwelt Medizin / Pharmazie
Naturwissenschaften Biologie
Technik
ISBN-10 0-367-51834-1 / 0367518341
ISBN-13 978-0-367-51834-9 / 9780367518349
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Erkennen wichtiger Arten an Straßen- und Parkbäumen

von Antje Lichtenauer; Thomas Kowol; Dirk Dujesiefken

Buch | Softcover (2022)
Haymarket Media (Verlag)
10,00

von David Sadava; Jürgen Markl; David M. Hillis …

Buch (2019)
Springer Spektrum (Verlag)
109,99